Emergency use listing of Covaxin discussed between Indian Health Minister and WHO Chief
Union Health Minister Mansukh Mandaviya and WHO chief Tedros Adhanom Ghebreyesus discussed a wide range of issues around Covid -19 and the emergency use of Bharat Biotech’s Covaxin and resuming the supplies of AstraZeneca vaccine to the COVAX facility over a phone conversation.
In his tweet, WHO chief mentioned “Had a call with @mansukhmandviya, India’s Health Minister, to discuss #India’s ongoing #COVID19 vaccination programme; the need for a global pandemic agreement; digital health; & traditional medicine. We welcome India’s support to strengthen WHO, incl. via flexible, sustainable financing”. The Director-General, WHO also had a discussion with Mandaviya on “the resumption of SII/AstraZeneca vaccine supplies to COVAX; the Covaxin Emergency Use Listing process; and technology and license sharing through C-TAP.”
The health minister also mentioned about his detailed interaction with the WHO chief and accompanying senior health officials in a tweet. The discussions revolved around various issues related to health, including pandemic management and WHO reforms.
Approximately 74.45 % of the total population has been administered the first dose of the covid vaccine, whereas 30.63% have received both doses. India is very close to crossing the 100 crore mark in the total cumulative number of covid vaccines being administered.
WHO mentioned in a tweet, “We are aware that many people are waiting for WHO’s a recommendation for Covaxin to be included in the Covid-19 Emergency Use Listing. We cannot cut corners before recommending a product for emergency use, we must evaluate it thoroughly to make sure it is safe and effective”.
India is also expected to resume export of surplus Covid-19 vaccine in the fourth quarter of 2021 under its Vaccine Maitri Programme.
post_id:
uld_count:
Cookie not set
Like
Dislike
Value 1: 0
Value 2: 10
